Alivus Life Sciences (ALVUS) investor relations material

Executive summary

• Q1 FY27 saw revenue of INR 640 crore (₹6,404.14 million), up 6.4% YoY, with strong non-GPL business growth offsetting a sharp GPL decline, driven by new product launches and robust demand across geographies.

• Gross margin improved to 60.2% (up 510 bps YoY), and EBITDA margin rose to 36.6% (up 650 bps YoY), reflecting favorable product mix and operational efficiencies.

• PAT for the quarter was INR 160 crore (₹1,600.76 million), with a PAT margin of 25%.

• Chronic therapies (CVS and CNS) contributed 58% to revenue; chronic therapies made up 72% of the top line.

• Unaudited financial results for the quarter ended June 30, 2026, were approved by the Board on July 30, 2026.

Financial highlights

• Revenue from operations: INR 640 crore (₹6,404.14 million), up 6.4% YoY.

• Gross profit: INR 385 crore (+16.3% YoY); gross margin: 60.2% (+510 bps YoY).

• EBITDA: INR 234 crore (+29.1% YoY); EBITDA margin: 36.6% (+650 bps YoY).

• PAT: INR 160 crore (₹1,600.76 million); PAT margin: 25%.

• Free cash flow: INR 90 crore (₹901 million); cash and equivalents: INR 880 crore (₹8,802 million) as of June 30, 2026.

Outlook and guidance

• Revenue growth guidance for FY27 is 10%-12%, with growth skewed towards H2.

• EBITDA margin guidance is 30%-32%, with potential upside to 34% if macro conditions remain stable.

• GPL business expected to remain flat for FY27, with stronger performance in H2.

• Non-GPL business momentum expected to continue, supported by a robust product pipeline and ongoing investments in capacity expansion.

• The company continues to operate as a single segment focused on APIs.